Examples of the cancer drugs that displaced previously approved therapies include alectinib for anaplastic lymphoma kinase rearrangement–positive metastatic NSCLC, osimertinib for epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution NSCLC, atezolizumab and bevacizumab for unresectable or metastatic hepatocellular carcinoma, and cabozantinib for advanced kidney cancer. Here, ALK is linked to cancer.